Evaluating FOLFIRINOX treatment for advanced pancreatic cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial evaluates the efficacy and safety of FOLFIRINOX treatment as a first-line chemotherapy for patients with unresectable locally advanced or metastatic pancreatic cancer. Participants will receive a maximum of 16 courses of treatment, divided into two sets of 8 courses, followed by maintenance therapy until disease progression. The study aims to determine how effective this regimen is in improving patient outcomes compared to existing treatments.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male or female age \> 18 years at time of study entry
* Performance status of 0 or 1 according to the Eastern Cooperative Oncology Group (ECOG)
* Patients with pancreatic adenocarcinoma
* Patients with unresectable locally advanced pancreatic cancer or metastatic pancreatic cancer
* Patients with no history of chemotherapy (prior adjuvant or neoadjuvant chemotherapy accepted if the time between the end of chemotherapy and recurrence is greater than 12 months) and no history of curative radiotherapy for metastatic or locally advanced disease. Palliative radiotherapy is accepted.
* Patient eligible for treatment with FOLFIRINOX (5-FU, Irinotecan, Oxaliplatin and folinic acid) including but not limited to: No active heart disease An ECG with a QT/QTc interval ˂ to 450 ms for men and ˂ to 470 ms for women. No uncontrolled hypertension defined by systolic pressure \> 140 mmHg or diastolic pressure \> 90 mmHg despite optimal medical management. A negative pregnancy test if applicable
* Tumor evaluation (CT scan) performed within 4 weeks (28 days) prior to inclusion with at least one measurable lesion according to RECIST 1.1 criteria
* Patient fit and able to comply with the protocol for the duration of the study, including treatment, visits, scheduled examinations and follow-up.
* Biological, hepatic, renal and serological data within the following limits (tests performed within 7 days of inclusion except for serologies performed within 28 days)
* Information given and informed consent signed
* Patient affiliated to a social security scheme
* Men and women must have an effective contraceptive method.

Exclusion Criteria:

* Patient with neuroendocrine carcinoma or acinar cell carcinoma
* Other cancer in the 5 years preceding inclusion or concomitant (except cancer in situ of the uterine cervix or cutaneous basal cell carcinoma).
* Presence of brain metastasis(es)
* Estimated prognosis \< 3 months
* History of grade 4 toxicity to oxaliplatin, irinotecan or 5FU if history of adjuvant/neoadjuvant chemotherapy
* Sequellar toxicity \> grade 1 if previous adjuvant/neoadjuvant chemotherapy
* Hypersensitivity to any component of FOLFIRINOX® treatment.
* Current participation or participation within 30 days prior to inclusion in another therapeutic trial with an investigational compound and/or completion of radiotherapy within 10 days prior to the start of treatment
* Evidence of a homozygous or heterozygous DPYD mutation and/or uracilemia \>16ng/mL and/or homozygous UGT1A1 genotype.
* Pregnancy, breastfeeding
* Inability to sign informed consent or to undergo medical monitoring of the trial for geographical, social or psychological reasons including, but not limited to, psychiatric illness compromising comprehension of information or conduct of the study.
* Patient under guardianship, curatorship or safeguard of justice.

Where it's running

• Centre Georges-François Leclerc
  Dijon, France Recruiting

Study contacts

• Study coordinator: Jean-David FUMET, Dr
• Email: jdfumet@cgfl.fr
• Phone: 380737538

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• First-line combo therapy with GnP, SHR-1701, and Apatinib for metastatic pancreatic cancer

  This trial tests whether adding SHR-1701 and Apatinib to standard GnP can safely and effectively treat previously untreated metastatic pancreatic cancer.

  Recruiting Phase 1/2 West China Hospital · Chengdu, Sichuan · NCT07802184

• Setidegrasib with mFOLFIRINOX or NALIRIFOX for KRAS G12D metastatic pancreatic cancer

  This trial tests whether adding setidegrasib to mFOLFIRINOX or NALIRIFOX helps people with metastatic pancreatic cancer who have a KRAS G12D mutation.

  Recruiting at 104 sites Phase 3 Astellas Pharma Inc · Gilbert, Arizona and 103 other locations · NCT07409272

• GFH375 plus chemotherapy in KRAS G12D-mutant metastatic pancreatic cancer

  This trial tests GFH375 in combination with standard chemotherapy to see if it helps people with KRAS G12D-mutant metastatic pancreatic cancer who have already been treated fail or progress on prior therapy.

  Recruiting Phase 3 Genfleet Therapeutics (Shanghai) Inc. · Beijing, Beijing Municipality · NCT07262567

• QL1706 plus chidamide with gemcitabine and nab-paclitaxel as first-line therapy for metastatic pancreatic cancer

  This study will test whether adding QL1706 and chidamide to standard gemcitabine plus nab‑paclitaxel helps people with newly diagnosed metastatic pancreatic adenocarcinoma.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin · NCT06951997

• Kinisoquin to prevent blood clots in people with advanced pancreatic cancer

  This trial will test whether Kinisoquin can prevent blood clots in people starting chemotherapy for metastatic or locally advanced pancreatic cancer.

  Recruiting at 3 sites Phase 3 Quercis Pharma AG · Ventura, California and 2 other locations · NCT06861088

• Miami EMPIRE: Eradication of Metastatic Pancreatic Cancer with Immuno-Radiation

  This trial will try adding targeted radiation to two immune checkpoint drugs, botensilimab and balstilimab, for adults with metastatic pancreatic ductal adenocarcinoma who progressed after at least one prior systemic therapy.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT06843551

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.